Gilead Sciences, Inc.
GILD
$133.37
-$1.57-1.16%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.39% | 4.69% | 2.97% | 1.84% | -0.28% |
| Total Other Revenue | -- | -- | -- | 0.00% | -- |
| Total Revenue | 4.39% | 4.70% | 2.97% | 1.84% | -0.28% |
| Cost of Revenue | -6.17% | 2.47% | -0.32% | -2.78% | -0.77% |
| Gross Profit | 7.57% | 5.29% | 3.84% | 3.16% | -0.14% |
| SG&A Expenses | 16.69% | -4.51% | -4.11% | -0.80% | -10.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.05% | -1.80% | -2.61% | 1.13% | -6.46% |
| Operating Income | 6.55% | 17.77% | 10.64% | 2.97% | 11.47% |
| Income Before Tax | 56.46% | -4.15% | 280.86% | 18.32% | 136.77% |
| Income Tax Expenses | 67.37% | -127.27% | 298.32% | 6.85% | 206.03% |
| Earnings from Continuing Operations | 53.69% | 22.43% | 143.58% | 21.44% | 131.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.69% | 22.43% | 143.58% | 21.44% | 131.53% |
| EBIT | 6.55% | 17.77% | 10.64% | 2.97% | 11.47% |
| EBITDA | 4.94% | 13.75% | 8.64% | 2.27% | 9.02% |
| EPS Basic | 54.18% | 23.02% | 144.36% | 21.63% | 131.56% |
| Normalized Basic EPS | 7.95% | 19.44% | 12.38% | 3.86% | 11.49% |
| EPS Diluted | 54.81% | 23.42% | 143.00% | 20.93% | 131.10% |
| Normalized Diluted EPS | 8.04% | 19.43% | 12.03% | 3.36% | 10.34% |
| Average Basic Shares Outstanding | -0.32% | -0.48% | -0.32% | -0.16% | -0.08% |
| Average Diluted Shares Outstanding | -0.40% | -0.48% | 0.00% | 0.32% | 0.96% |
| Dividend Per Share | 3.80% | 2.60% | 2.60% | 2.60% | 2.60% |
| Payout Ratio | -0.33% | -0.17% | -0.58% | -0.16% | 4.24% |